Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 6c; Issues Light Q3, FY12 Outlook

Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q2 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $197 million versus the consensus estimate of $191.51 million.

Medicis Pharmaceutical Corp. sees Q3 2012 EPS of $0.41-$0.58, versus the consensus of $0.78. Medicis Pharmaceutical Corp. sees Q3 2012 revenue of $185-$200 million, versus the consensus of $221.95 million.

Medicis Pharmaceutical Corp. sees FY2012 EPS of $2.25-$2.65, versus the consensus of $2.74. Medicis Pharmaceutical Corp. sees FY2012 revenue of $800-$834 million, versus the consensus of $846.4 million.

Medicis Pharmaceutical Corp. sees Q4 2012 EPS of $0.72-$0.95. Medicis Pharmaceutical Corp. sees Q4 2012 revenue of $216-$235 million.

For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
• AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says